Success Stories: NIW Approval Confirmed in Just 1 Month for a Chinese Postdoctoral Research Scientist in Biochemistry, Thanks to our Case Prepping and Premium Processing Upgrade

Client’s Testimonial:

“It was a great experience working with your team. Thanks a lot for your effort.”

On February 9^th, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Research Scientist in the Field of Biochemistry (Approval Notice).

General Field: Biochemistry

Position at the Time of Case Filing: Postdoctoral Research Scientist

Country of Origin: China

State of Residence at the Time of Filing: California

Approval Notice Date: February 9^th, 2023

Processing Time: 1 month (Premium Processing Requested)

Case Summary:

“The substantial merit of [the client’s] work is undeniable. Her research is critical to increasing our ability to discover novel therapeutic monoclonal antibodies that minimize the dosage of antibodies required to treat specific conditions. To this end, [the client] has been developing a protein engineering strategy that produces antibodies with improved dose potency, demonstrating the inherent usefulness of her work. Her research directly addresses global problems related to the ineffectiveness of therapeutic drugs that are currently available.”

The above statement was issued as a part of a longer letter of recommendation written for our client from China by an expert in the field of biochemistry. As is evident, our client was clearly a very respected member of the scientific community due to the far-reaching significance of her research. Hailing from China, she had a Ph.D. in oral biology and was working as a postdoctoral research scientist while applying for NIW approval to the USCIS.

Our team has worked with thousands of NIW petitioners in the past and knew what ticked the boxes for the adjudicating bench at the USCIS. So we collected relevant information from her academic and professional career such as the following:

As an expert in the field her proposed endeavor is to continue her research on advancing novel protein characterization approaches for discovering and engineering antibodies in order to develop new therapeutics that target difficult diseases.
Her work advancing her proposed endeavor is of great importance because it progresses therapeutics in order to reduce the burden of various diseases that contribute significantly to global morbidity and mortality.
Her proposed endeavor also has broad implications for the United States since her work had led to the discovery of more effective treatments for acute liver injury caused by acetaminophen/paracetamol (APAP).
Due to its clear national importance, her work has in fact been supported with funding from the National Institutes of Health (NIH), the National Basic Research Program of China (973 Program), and the National Natural Science Foundation of China.
Academically, she has completed at least 3 reviews to date and her research has resulted in 7 peer-reviewed journal articles (4 of them first-authored) which have been cited a total of 82 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of biochemistry.
The 4 letters of recommendation also assisted in getting the case approved.

All of these factors played in her favor and won her the approval in just 1 month’s time. This was made possible by our team’s excellent case preparation and premium processing upgrade. We thank our client for choosing us and we wish her success in her future endeavors.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.